Skip to main content
OpenTrials
Completed

NCT Number: NCT01815307

Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer

To compare efficacy and safety of Gemcitabine versus S-1 adjuvant therapy after hemihepatectomy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Osaka University, Graduate School of Medicine

Osaka, 565-0871, Japan

About this study

There is no standard adjuvant therapy after liver hemi-hepatectomy due to bile duct cancer, because of high surgical morbidity ratio and high adverse event ratio of adjuvant therapy. For example, our preliminary results showed that regular gemcitabine administration (1000mg/m2, day 1, 8, 15 every 4 weeks) after hemihepatectomy was too toxic and induced severe leukocytopenia and/or thrombocytopenia. Formerly, the investigators planned the study to decide more safety adjuvant protocol (recommend dose: RD) for Gemcitabine or S-1 after hemihepatectomy using Continuous Reassessment Method (CRM) analysis and decided the recommend doses. Note: In the former study, the investigators decided that tolerable ratio of Dose Limiting Toxicity (DLT) would be less than 10%.

Herein, the investigators planned the study to evaluate efficacy (recurrent free survival as primary outcome, and overall-survival as secondary outcome) and safety (as secondary outcome) in our recommended protocols, and to compare the efficacy as randomized control trial.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Biliary tract cancer (BTC) (>= Unio Internationalis Contra Cancrum (UICC) Stage IB), adenocarcinoma
  • R0 or R1 resection
  • no obvious recurrent lesion
  • 20 years old or more
  • Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1
  • The patient underwent no other treatment than surgery for BTC
  • Neutrophil must be over 1500/μl, Hemoglobin must be over 9.0g/dL, platelet must be over 100,000/μl, Aspartate transaminase (AST) and Alanine aminotransferase (ALT) must be less than 150 IU/L, total bilirubin must be less than 1.5 mg/dL, Creatinine must be less than 1.2 mg/dl, and Creatinine clearance must be over 60 mL/min
  • The patient can intake drugs per os.
  • From 4 to 12 weeks after the surgery
  • Written informed consent

Exclusion criteria

  • Existence of active double cancer
  • The patient suffered from severe drug allergy
  • Sever complications (interstitial pneumonia, heart failure, renal failure, liver failure, ileus, incontrollable diabetes mellitus, and so on)
  • Any active infections exist.
  • Pregnancy
  • Severe mental disorder
  • Others

Treatment and study plan

Gemcitabine

Drug

1000mg/m2, day 1 every 2 weeks

Other names: gemzer

S-1

Drug

80mg/m2/day, day 1-28, every 6 weeks

Other names: TS-1

Primary outcomes

  1. 1 year recurrent free survival rate

    Time frame: One year

    Duration: From randomization to evidenced recurrence or death. Rate: Number of patients with evidenced recurrence or death / number of total patients.

    1 year recurrent free survival rate: recurrent free survival rate at one-year from the randomization

Secondary outcomes

  1. Two-year recurrent free survival rate

    Time frame: Two years

  2. One-year overall survival rate

    Time frame: One year

  3. Two-year overall survival rate

    Time frame: Two years

  4. Completion rate of the protocol treatment

    Time frame: 6 months

  5. Dose intensity of anti-tumor drugs

    Time frame: 6 months

  6. Rate and grade of adverse events or adverse drug reactions

    Time frame: 6 months

  7. Duration of recurrent free survival

    Time frame: an expected average of 2 years

  8. Duration of overall survival

    Time frame: an expected average of 3 years

Sponsors and collaborators

Lead sponsor

Kansai Hepatobiliary Oncology Group

Network

Registry information

Official study title

Randomized Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer

Important dates

Study start
2013
Primary completion
2016
Study completion
2017
First posted
Mar 21, 2013
Registry last updated
May 16, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.